Evaluation and analysis of bleeding risk of anticoagulation therapy in severe non-ICU patients with COVID-19 based on heparinase-modified TEG
Journal Title: Chinese Journal of Blood Transfusion - Year 2024, Vol 37, Issue 3
Abstract
Objective To investigate the clinical application of heparinase-modified TEG (hmTEG) in evaluating coagulation status and monitoring anticoagulant therapy in severe non-ICU patients with COVID-19. Methods The clinical data of severe non-ICU patients with COVID-19 confirmed to be infected with novel coronary disease (SARS-CoV-2) from December 2022 to May 2023 were analyzed retrospectively. The patients were divided into therapeutic dose group and prophylactic dose group according to the initial dose of enoxaparin. The changes of platelet count, activated partial thromboplastin time, prothrombin time, thrombin time, fibrinogen, D-dimer, TEG and hmTEG before and after heparin treatment were compared between the two groups, so as to evaluate the changes of coagulation function and bleeding risk of COVID-19 severe non-ICU patients after anticoagulation with different doses of heparin. Results A total of 179 severe non-ICU patients with COVID-19 were enrolled in this study, including 102 patients in therapeutic dose group and 77 patients in prophylactic dose group. Before receiving heparin anticoagulation, except for age(63.4±11.6 vs 59.8±9.1) D-dimer(678 ng/mL vs 621 ng/mL) and MA values [(69.1±10.2)mm vs (65.6±8.5)mm], there were no statistical differences in platelet count, activated partial thromboplastin time, prothrombin time, thrombin time, fibrinogen, R value, K time, α angle and coagulation index (CI) between the therapeutic dose group and the prophylactic dose group (P>0.05). After receiving heparin anticoagulation, there were significant differences in CKR value [(12.2±4.1)min vs (10.2±3.3)min] and CKHR value [(8.1±3.2)min vs (7.1±2.6)min] between therapeutic dose group and prophylactic dose group (P<0.05), but no significant differences in other parameters between groups (P>0.05). Meanwhile, the proportion of heparin overdose in the therapeutic dose group was significantly higher than that in the prophylactic dose group 15.69%(16/102) vs 5.19%(4/77)(P<0.05). However, there was no difference in the incidence of VTE events 2.35 %(2/85) vs 2.78%(2/72), gastrointestinal bleeding 2.35%(2/85) vs 1.39%(1/72), ICU admission 4.71%(4/85) vs 4.17%(3/72) and death events 3.53%(3/85) vs 2.78%(2/72) between the two groups (P>0.05). Conclusion In the current epidemic trend of COVID-19, in order to reduce the occurrence of bleeding events, the heparin dose should be selected more carefully in the prevention of thrombosis in severe non-ICU patients with COVID-19. The individualized assessment of bleeding risk by hmTEG is more conducive to the adjustment and control of heparin dose.
Authors and Affiliations
Ying ZHONG, Xianwen HUANG, Chunfeng LIANG
Keywords
Related Articles
- EP ID EP738782
- DOI 10.13303/j.cjbt.issn.1004549x.2024.03.009
- Views 57
- Downloads 0
Introduction to the European Guideline on Management of Major Bleeding and Coagulopathy Following Trauma (sixth edition)
In the European Guideline on Management of Major Bleeding and Coagulopathy Following Trauma updated recently, there are 39 clinical practice recommendations that follow an approximate temporal path for management of the...
Platelet lncRNA as a biomarker for early screening of lung adenocarcinoma: a preliminary study
Objective To explore the diagnostic value of platelet long non-coding RNA (lncRNA) as a biomarker for early screening of lung adenocarcinoma (LUAD). Methods The GSE183635 and GSE89843 datasets, which contained the platel...
Research progress on massive transfusion protocol
Massive transfusion protocol (MTP) is a programmatic procedure for massive blood transfusions, which is an important means of patient blood management (PBM) for trauma and massive hemorrhage patients. MTP can be initiate...
Serological follow-up of anti-SARS-CoV-2 antibodies in blood donors after COVID-19 vaccine booster dose and breakthrough infections in Fuzhou
Objective To analyze the dynamics of specific SARS-CoV-2 IgG antibodies in blood donors in Fuzhou area after receiving booster doses of inactivated COVID-19 vaccine and breakthrough infections, and to provide evidence fo...
Research on characteristics of potential blood donors and influencing factors of blood donation intention
Objective To investigate the demographic characteristics and factors affecting the willingness to donate blood among potential donors in China, so as to improve the recruitment efficiency for blood donors. Methods Non-bl...